Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

N-Acetylfarnesylcysteine Is a Novel Class of Peroxisome Proliferator-activated Receptor γ Ligand with Partial and Full Agonist Activity in Vitro and in Vivo

7 Oct 2011

Abstract excerpt

The thiazolidedione (TZD) class of drugs is clinically approved for the treatment of type 2 diabetes. The therapeutic actions of TZDs are mediated via activation of peroxisome proliferator-activated receptor γ (PPARγ). Despite their widespread use, concern exists regarding the safety of currently used TZDs. This has prompted the development of selective PPARγ modulators (SPPARMs), compounds that promote glucose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipose Tissue and Metabolism
Share to Metabolism, Diabetes, and Cancer
Share to Peroxisome Proliferator-Activated Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21979952
DOI: 10.1074/jbc.m111.257915

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

N-Acetylfarnesylcysteine Is a Novel Class of Peroxisome Proliferator-activated Receptor γ Ligand with Partial and Full Agonist Activity in Vitro and in VivoPMID 21979952Read ↗

Small molecule inhibitor of PPARγ acetylation promotes insulin sensitization and browning of white adipose tissue with improved safetySemantic proximity Read ↗

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH modelSemantic proximity Read ↗

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.Semantic proximity Read ↗

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentSemantic proximity Read ↗

PPAR gamma as a metabolic regulator: insights from genomics and pharmacology.Semantic proximity Read ↗

Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.Semantic proximity Read ↗

PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part I: PPAR-αSemantic proximity Read ↗

PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.Semantic proximity Read ↗

Identification of PTGR2 inhibitors as a new therapy for diabetes and obesitySemantic proximity Read ↗

PPARα as a therapeutic target in inflammation-associated diseasesSemantic proximity Read ↗

PPARs and their Effects on the Cardiovascular SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.